Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia
Conditions:  Acute Myeloid Leukemia;  Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Recurrent Acute Myeloid Leukemia;  Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Refractory Acute Myeloid Leukemia;  Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Interventions:  Drug: Decitabine;  Drug: Ponatinib;  Drug: Venetoclax Sponsors:  M.D. Anderson Cancer Center;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Research